COMPANY:

DermTech

"DermTech, Inc...announced that it is participating in the 2023 American Academy of Dermatology (AAD) Annual Meeting, which will take place on March 17-21 in New Orleans...DermTech will present four new posters focused on topics including the efforts in development of a basal cell carcinoma diagnostic gene signature and evaluation of the DermTech Melanoma Test (DMT) in higher Fitzpatrick Skin Types."

"DermTech, Inc...announced an agreement with a Blues plan in Arizona. The agreement makes the foundational assay of the DermTech Melanoma Test (DMT) available to the approximately 1.9 million members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV)."

"DermTech, Inc...announced that U.S. General Services Administration has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA)."

"DermTech, Inc...announced favorable coverage policies from two commercial payers comprising a Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. The coverage policies resulted from an independent technology assessment by the second largest laboratory benefits manager in the U.S. and are similar to the Medicare coverage policy of the Company’s foundational assay included in the DermTech Melanoma Test (DMT)."

"DermTech, Inc...announced that the Defense Health Agency’s Lab Joint Working Group has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by TRICARE. TRICARE is the health care program for uniformed service members, retirees and their families around the world."

"DermTech, Inc...announced favorable coverage policies from four commercial payers including Blue Cross Blue Shield of North Carolina (BCBS NC), Blue Cross Blue Shield of South Carolina (BCBS SC), Blue Cross Blue Shield of Louisiana (BCBS LA) and Blue Cross Blue Shield of Kansas City (BCBS KC). These coverage policies were announced pursuant to an independent technology assessment by the second largest laboratory benefits manager in the U.S. and are similar to the policy issued by Medicare for coverage of the Company’s foundational assay for the DermTech Melanoma Test (DMT)."

"DermTech, Inc...announced...an agreement with Sonora Quest Laboratories (Sonora Quest)...to expand access to enhanced melanoma detection. As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network of healthcare providers...The DermTech Melanoma Test uses a non-invasive Smart Sticker™ to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma."

"DermTech, Inc...announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. 3-4 in San Diego...The presentation, titled 'Translational Research to Revolutionize Dermatologic Care,' emphasized the Company’s proprietary Smart Sticker™ and platform technology, highlighting its capabilities, specializations and advantages."

"DermTech, Inc...announced that its chief medical officer, Dr. Loren Clarke, will present study data illustrating how genomic technology can enhance melanoma detection and improve patient care at America’s Health Insurance Plans (AHIP) 2022. The meeting is being held from June 21-23, 2022 in Las Vegas, Nev...Title - Transforming the Future of Dermatology Through Genomic Innovation..."

"DermTech, Inc...announced today that it is sponsoring The Sun Bus, a community service provided by the Colorado Melanoma Foundation in partnership with Epiphany Dermatology, to bring free skin cancer screenings and public education to communities across the U.S. The Sun Bus is a mobile screening station and sun safety classroom that is expected to serve more than 50 locations nationwide in 2022."

"DermTech, Inc...announced today that SKIN: The Journal of Cutaneous Medicine has published its original research study...By incorporating the Pigmented Lesion Assay ('PLA') into the current care pathway of assessing pigmented skin lesions or moles suspicious for melanoma, the study highlights the potential reduction in cost for commercial health insurance plans, in addition to a higher quality of care for patients and improved health outcomes."

"BioIQ, Inc...nd DermTech, Inc...announced an agreement to bring increased patient access to precision genomics. The DermTech Melanoma Test is now included in BioIQ's lineup of testing options for employee and member health programs. The program will be available in Florida initially with planned expansion to other states."

"DermTech, Inc...announced today the expansion and branding of its translational medicine service offering, DermTech Stratum™, which utilizes DermTech’s non-invasive technology and precision biomarker approaches to bring heightened precision and personalization to dermatologic disease diagnosis and treatment development...The DermTech Stratum service offering is appropriate for indications where skin is the target or a surrogate target organ and are being used to support drug discovery and development programs focused on cancers and inflammatory diseases in clinical research studies."

"DermTech, Inc...announced today an agreement to make the DermTech Melanoma Test available through DermatologistOnCall’s telemedicine platform. The millions of patients served through DermatologistOnCall will now have increased access to DermTech’s non-invasive, precision genomics tests for melanoma, the leading cause of skin cancer deaths...The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via the DermTech Smart Sticker™. A patient sample can be collected at home under virtual supervision by a trained DermatologistOnCall clinician. The sample is sent to the DermTech Gene Lab where it is tested for genomic markers linked to melanoma."